Work

Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics

Year: 2020

Type: article

Abstract: There is an urgent need for novel agents to treat drug-resistant bacterial infections, such as multidrug-resistant Staphylococcus aureus (MRSA). Desirable properties for new antibiotics include high potency, narrow species selectivity, low propensity to elicit new resistance phenotypes, and synergy with standard-of-care (SOC) chemotherapies.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.01707-20

Authors: Yongliang Fang, Jack R. Kirsch, Liang Li, Seth A. Brooks, Spencer Heim, Cynthia Tan, Susan Eszterhas, Hao D. Cheng, Hongliang Zhao, Yan Q. Xiong, Karl E. Griswold

Institutions: Dartmouth College, University of California, Los Angeles, The Lundquist Institute, Harbor–UCLA Medical Center

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases

Awards: Design and Development of Immunotolerant S. aureus Biotherapies, Design and Development of Immunotolerant S. aureus Biotherapies, Cancer Center Support Grant, The Institute for Biomolecular Targeting

OpenAlex ID: W3111749708

FWCI: 0.36

Cites: 63

Cited by: 15

Related to: 10